Page last updated: 2024-08-24

simendan and HIV Infections

simendan has been researched along with HIV Infections in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hayashi, T; Huang, H; Jean, M; Santoso, NG; Simpson, S; Zhu, J	1

Other Studies

1 other study(ies) available for simendan and HIV Infections

Article	Year
Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral research, 2017, Volume: 146 Topics: Anti-HIV Agents; Cell Line; Drug Approval; Drug Discovery; Gene Expression Regulation, Viral; HIV Infections; HIV Long Terminal Repeat; HIV-1; Humans; Hydrazones; Pyridazines; Simendan; Small Molecule Libraries; Transcription, Genetic; Virus Activation; Virus Latency	2017

Article

Year

Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.

Antiviral research, 2017, Volume: 146

Topics: Anti-HIV Agents; Cell Line; Drug Approval; Drug Discovery; Gene Expression Regulation, Viral; HIV Infections; HIV Long Terminal Repeat; HIV-1; Humans; Hydrazones; Pyridazines; Simendan; Small Molecule Libraries; Transcription, Genetic; Virus Activation; Virus Latency

2017